Stock Spotlight: Telix Pharmaceuticals Ltd (ASX:TLX)

About Telix Pharmaceuticals Ltd

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Source:EODHD

Key Stats

Source: EODHD. Data as of 01/05/26.

Growth Potential

• TLX is pivoting from a single product, single-market company to a multi-product, multi-region commercial organization.
• Market share gains as TLX continues to roll out Illuccix & Gozellix globally - imaging agents to help detect prostate cancer. TLX is rolling out Illuccix across Europe (now in 16 countries) and the launch of Zircaix & Pixclara. Management has not included any revenue uplift from launching Zircaix in their FY26 guidance.  
• Being a vertically integrated radiopharma provides a competitive advantage and certainty of supply (scale efficiently) – recent acquisitions have increased manufacturing and distribution sites to 38 globally.  
• TLX is building its next generation pipeline including alpha therapy candidates. TLX has 10 early and late-stage assets. Late-stage assets primarily focus on beta therapies, followed by earlier-stage assets exploring alpha therapies.
• Self-funded – TLX is looking to utilise revenue growth from its current products to fund TLX asset pipeline and infrastructure. Investors should view TLX not as an EPS growth story but rather as a self-funded biotech company. With maturity of assets, the Company is more likely to resemble a healthcare company in 2028. 
  

Key Risks

• Product pipelines fail to deliver or adverse read-out from phase studies. This also includes clinical execution of these trials.
• Competitive pressures (including pricing). The radiopharma market is highly competitive with significant investment by competitors that could limit TLX upside. Furthermore, alternative treatments could emerge.
• Product launch and uptake risk. While Illuccix has achieved notable commercial success, there is no assurance that the company’s pipeline or future products will gain similar traction with healthcare providers or patients. Each product launch carries the risk of limited clinical adoption or competitive displacement.
• Regulatory risks. The pharmaceutical industry is inherently complex, with market dynamics influenced by regulatory frameworks, clinical trial outcomes, and evolving treatment standards.